title: Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess.
abstract: The aim of our study was to investigate the effect of hexarelin, a novel GH-releasing peptide-6 analog, and GH-releasing hormone (GHRH) (alone or in combination) on GH secretion in adult patients with increased somatostatin tone due to chronic glucocorticoid excess. We studied seven adult patients undergoing long-term (no less than 6 months) immunosuppressive glucocorticoid treatment for non-endocrine diseases (six females and one male, age range 42-68 years) and one subject (female, age 31 years) with endogenous hypercortisolism due to adrenal adenoma. Six normal subjects (four females and two males) matched for sex and age with the patients and not undergoing any therapy served as controls. All the subjects underwent the following three tests in random order: (1) human GHRH (1-29)NH2 (100 micrograms in 1 ml saline) injected as an i.v. bolus at 0 min, (2) hexarelin (100 micrograms in 1 ml saline) injected as an i.v. bolus at 0 min and (3) hexarelin (100 micrograms in 1 ml of saline) plus GHRH (100 micrograms in 1 ml saline) injected as an i.v. bolus at 0 min. After GHRH alone the patients with glucocorticoid excess showed a blunted GH response as compared with normal subjects (median delta GH: 0.9, range 0-5.6 micrograms/l vs 7:1, range 0.3-14.9 micrograms/l). No significant differences were observed in the steroid-treated group with respect to normal subjects after hexarelin alone (median delta GH: 15.5, range 1.9-45.2 micrograms/l vs 17.9, range 5.5-53.9 micrograms/l).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Cattedra di Clinica Medica, University of Brescia, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Giustina
authors.forename: A R
authors.initials: AR
authors.lastname: Bussi
authors.forename: R
authors.initials: R
authors.lastname: Deghenghi
authors.forename: B
authors.initials: B
authors.lastname: Imbimbo
authors.forename: M
authors.initials: M
authors.lastname: Licini
authors.forename: C
authors.initials: C
authors.lastname: Poiesi
authors.forename: W B
authors.initials: WB
authors.lastname: Wehrenberg
mesh_terms: D000328:Adult; D000368:Aged; D018592:Cross-Over Studies; D004357:Drug Synergism; D005260:Female; D005938:Glucocorticoids / Q000097:blood*; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone; D006133:Growth Substances; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides; D016037:Single-Blind Method; D013268:Stimulation, Chemical
chemical_list: D005938:Glucocorticoids; D006133:Growth Substances; D009842:Oligopeptides; C086184:hexarelin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone